Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice
暂无分享,去创建一个
A. Ballestrero | F. Patrone | N. Stergiopulos | F. Mach | S. Steffens | S. Bruzzone | R. Fraga-Silva | F. Montecucco | M. Bertolotto | F. Dallegri | A. Quercioli | A. Nencioni | N. Vuilleumier | I. Caffa | R. D. da Silva | G. Pelli | F. Burger | S. Lenglet | Giovanna Sociali | M. Magnone | I. Bauer | K. Galan | M. Fabre | Robson Santos | G. Sociali | Sara Vázquez Calvo | Inga Bauer
[1] K. Schaller,et al. Treatment with Evasin-3 Reduces Atherosclerotic Vulnerability for Ischemic Stroke, but Not Brain Injury in Mice , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[2] A. Akhmedov,et al. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. , 2013, Antioxidants & redox signaling.
[3] M. Hristov,et al. Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes , 2013, EMBO molecular medicine.
[4] B. Cravatt,et al. Fatty Acid Amide Hydrolase Deficiency Enhances Intraplaque Neutrophil Recruitment in Atherosclerotic Mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[5] P. Murphy,et al. Regulation of Atherogenesis by Chemokines and Chemokine Receptors , 2013, Archivum Immunologiae et Therapiae Experimentalis.
[6] M. Hellmich,et al. Conditional Targeting of Tumor Necrosis Factor Receptor–Associated Factor 6 Reveals Opposing Functions of Toll-Like Receptor Signaling in Endothelial and Myeloid Cells in a Mouse Model of Atherosclerosis , 2012, Circulation.
[7] N. Stergiopulos,et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. , 2012, European heart journal.
[8] E. Mazzon,et al. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury , 2012, Journal of Neuroinflammation.
[9] Oliver Soehnlein,et al. Multiple roles for neutrophils in atherosclerosis. , 2012, Circulation research.
[10] R. Koenen,et al. Chemokines: established and novel targets in atherosclerosis , 2011, EMBO molecular medicine.
[11] O. Ratib,et al. Receptor activator of NF-κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability , 2011, Thrombosis and Haemostasis.
[12] C. Weber,et al. Atherosclerosis: current pathogenesis and therapeutic options , 2011, Nature Medicine.
[13] H. Tilg,et al. A key role for Pre–B cell colony–enhancing factor in experimental hepatitis , 2011, Hepatology.
[14] Oliver Soehnlein,et al. Hyperlipidemia-Triggered Neutrophilia Promotes Early Atherosclerosis , 2010, Circulation.
[15] F. Mach,et al. Single Administration of the CXC Chemokine-Binding Protein Evasin-3 During Ischemia Prevents Myocardial Reperfusion Injury in Mice , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[16] A. Gayet-Ageron,et al. Systemic and Intraplaque Mediators of Inflammation Are Increased in Patients Symptomatic for Ischemic Stroke , 2010, Stroke.
[17] R. Koenen,et al. Manipulating the chemokine system: therapeutic perspectives for atherosclerosis. , 2010, Current opinion in investigational drugs.
[18] R. Koenen,et al. Therapeutic targeting of chemokine interactions in atherosclerosis , 2010, Nature Reviews Drug Discovery.
[19] A. Ballestrero,et al. Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE , 2009, PloS one.
[20] B. K. Thakur,et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD+-sirtuin-1-dependent pathway. , 2009 .
[21] Véronique Kruys,et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner , 2009, Nature Medicine.
[22] O. Leo,et al. Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase/Visfatin Enzymatic Activity Identifies a New Inflammatory Pathway Linked to NAD , 2008, PloS one.
[23] P. Heeringa,et al. Accumulation of Myeloperoxidase-Positive Neutrophils in Atherosclerotic Lesions in LDLR−/− Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[24] S. Tonstad,et al. Increased Expression of Visfatin in Macrophages of Human Unstable Carotid and Coronary Atherosclerosis: Possible Role in Inflammation and Plaque Destabilization , 2007, Circulation.
[25] M. Karlsson,et al. CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome. , 2006, Anticancer research.
[26] F. Grosveld,et al. Atherosclerotic Lesion Size and Vulnerability Are Determined by Patterns of Fluid Shear Stress , 2006, Circulation.
[27] R. Terkeltaub,et al. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. , 2006, The American journal of pathology.
[28] M. Madsen,et al. Anticancer agent CHS 828 suppresses nuclear factor‐κB activity in cancer cells through downregulation of IKK activity , 2004, International Journal of Cancer.
[29] Max Hasmann,et al. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. , 2003, Cancer research.
[30] R. Graeff,et al. A novel cycling assay for cellular cADP-ribose with nanomolar sensitivity. , 2002, The Biochemical journal.
[31] I. Shimomura,et al. Nuclear Sterol Regulatory Element-binding Proteins Activate Genes Responsible for the Entire Program of Unsaturated Fatty Acid Biosynthesis in Transgenic Mouse Liver* , 1998, The Journal of Biological Chemistry.
[32] M. Gerritsen,et al. Novel Inhibitors of Cytokine-induced IκBα Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo* , 1997, The Journal of Biological Chemistry.
[33] Kazuyoshi Watanabe,et al. Glucocorticoid-mediated Gene Suppression of Rat Cytokine-induced Neutrophil Chemoattractant CINC/gro, a Member of the Interleukin-8 Family, through Impairment of NF-B Activation (*) , 1996, The Journal of Biological Chemistry.
[34] Ann Richmond,et al. HMGI(Y) and Sp1 in addition to NF-κB regulate transcription of the MGSA/GROα gene , 1995 .
[35] A. Richmond,et al. MGSA/GRO transcription is differentially regulated in normal retinal pigment epithelial and melanoma cells , 1994, Molecular and cellular biology.
[36] D. Scudiero,et al. New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.
[37] M. Gerritsen,et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. , 1997, The Journal of biological chemistry.
[38] A. Richmond,et al. HMGI(Y) and Sp1 in addition to NF-kappa B regulate transcription of the MGSA/GRO alpha gene. , 1995, Nucleic acids research.